Here’s what you should know:
1. BT-11 is an orally-active, gut-restricted therapeutic. Researchers conducted a randomized, double-blind trial of 70 patients to assess the drug’s safety.
2. The drug was well-tolerated in all 70 patients, with no dose-limiting toxicities.
3. Adverse events in the BT group were like that of the placebo group.
4. Researchers tested BT-11 doses between 7 mg/kg and 100 mg/kg. They did not reach a maximum tolerated dose.
5. Landos Chairman and CEO Josep Bassaganya-Riera, PhD, said, “The results of our Phase 1 study provide the first-in-human clinical data in support of BT-11 as a novel oral treatment for IBD. We are pleased to see that BT-11 was well-tolerated and safe in healthy volunteers.”
6. Landos will begin a phase 2 study in 2019.
More articles on gastroenterology:
The PE arms race — From the deal heard round the world to what’s next in GI
The strategy behind Pardee UNC’s $16M ASC
ASC supply chain tip of the day: Find an accountability structure
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.